SCHEMBL4547798

SCHEMBL4547798

CC(C)(C)n1c(=O)c2ccccc2n(C(C)(C)C)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.44
FEN1 P39748 1/20 0.44
ERCC4 Q92889 1/20 0.44
PGR P06401 3/20 0.42
SLC6A2 P23975 1/20 0.40
MAPK8 P45983 1/20 0.39
NPEPPS P55786 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CNR2 P34972 1/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
HSD17B10 Q99714 2/20 0.37
GAA P10253 1/20 0.37
PKM P14618 1/20 0.37
CASP1 P29466 1/20 0.37
GALK1 P51570 1/20 0.37
BLM P54132 1/20 0.37
CASP7 P55210 1/20 0.37
SAE1 Q9UBE0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14584044 0.83 SLC6A2 (0.45) ERCC1FEN1ERCC4PGRSLC6A2
SCHEMBL12142342 0.82 PGR (0.46) ERCC1FEN1ERCC4PGRSMN1; SMN2
SCHEMBL22672846 0.81 SMN1; SMN2 (0.50) ERCC1FEN1ERCC4PGRSLC6A2
SCHEMBL6391657 0.79 ERCC1 (0.41) ERCC1FEN1ERCC4PGRSLC6A2
SCHEMBL24119301 0.78 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1HSD17B10GAAKDM4E
SCHEMBL18119022 0.78 ALDH1A1 (0.53) SLC6A2ALDH1A1HSD17B10GAAKDM4E
SCHEMBL29625463 0.77 GPR3 (0.52) KMT2AALDH1A1LMNAHSD17B10KDM4E
SCHEMBL2608424 0.77 GPR3 (0.52) KMT2AALDH1A1LMNAHSD17B10KDM4E
SCHEMBL4547801 0.75 KDM5A (0.41) FEN1
SCHEMBL7656674 0.75 CNR2 (0.46) PGRSMN1; SMN2CNR2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501749-B2 Azaquinazolinediones chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-08-06 US disclosed
US-20120108597-A1 Azaquinazolinediones Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108597-A1 Azaquinazolinediones Chymase Inhibitors CMA1, SERPINB1, CTSC ERCC1 4325/4885FEN1 2027/4885ERCC4 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.